Patent intelligence · US
US 6013122
Tattoo inks
Tattoo inks
Patent details — US 6013122
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jan 11, 2000
- Expiration
- Jan 6, 2020
- Applicant
- Option Technologies Corp.
- Claims
- 16
- CPC classes
- A61K, A61K8/14, A61K8/65, A61K8/733
Quick answer
US 6013122 (Tattoo inks) is held by Option Technologies Corp.. Status: expired. Granted Jan 11, 2000. Expires Jan 6, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Option Technologies Corp.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K8/14, A61K8/65, A61K8/733, A61K8/8129, A61K8/85
More from Option Technologies Corp.
Related pharmaceutical patents in our USPTO index.
-
US 11596610
Compositions in support of health and mental accuity
granted -
US 10117937
Highly branched alpha-D-glucans
granted -
US 9289513
Targeted cytokine for treatment of musculoskeletal diseases
granted -
US 8685932
Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
granted -
US 6770283
DNA expression systems based on alphaviruses
expired -
US 6692750
Alphavirus expression vector
expired -
US 6566093
Alphavirus cDNA vectors
expired -
US 6224879
Alphavirus expression vector
expired
Frequently asked questions
What is US patent 6013122?
US 6013122 (Tattoo inks) is held by Option Technologies Corp.. Status: expired. Granted Jan 11, 2000. Expires Jan 6, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6013122?
Option Technologies Corp. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 6013122 expire?
Our index shows an expiration date of Jan 6, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.